Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
1001 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 65
1002 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 61
1003 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 65
1004 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 19
1005 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
1006 Apheresis Allogeneic Mixed Phenotype Acute Leukemia Hematology 2025 Standard Therapy Poland 47
1007 Apheresis Allogeneic Polycythemia Vera Hematology 2025 Standard Therapy Poland 61
1008 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 56
1009 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 53
1010 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 55
1011 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Poland 34
1012 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 50
1013 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2025 Standard Therapy Poland 71
1014 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy Poland 64
1015 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 54
1016 Apheresis Autologous Non-Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 50
1017 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 50
1018 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 35
1019 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 54
1020 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
1021 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
1022 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 55
1023 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 64
1024 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 68
1025 Apheresis Allogeneic Primary myelofibrosis Hematology 2025 Standard Therapy Germany 71
1026 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 47
1027 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 58
1028 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 68
1029 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 44
1030 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 59
1031 Apheresis Autologous Lymphoma Non-Hodgkin Hematology 2025 Standard Therapy Portugal 58
1032 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 59
1033 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 2
1034 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 41
1035 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy France 48
1036 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 64
1037 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy United Kingdom 63
1038 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 64
1039 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 58
1040 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Poland 68
1041 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Germany 59
1042 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 56
1043 Apheresis Allogeneic Diffuse Large B-cell Lymphoma Hematology 2025 Standard Therapy Belarus 53
1044 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 60
1045 Apheresis Allogeneic Immunodeficiency – LRBA Hematology 2025 Standard Therapy Turkey 14
1046 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Poland 20
1047 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 65
1048 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 54
1049 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 75
1050 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 58
1051 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 48
1052 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 37
1053 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Chile 40
1054 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1055 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Switzerland 65
1056 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Portugal 68
1057 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Estonia 9
1058 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 63
1059 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 67
1060 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 45
1061 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 59
1062 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 69
1063 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 64
1064 Apheresis Allogeneic Acute lymphoblastic leukemia Hematology 2025 Standard Therapy Germany 42
1065 Apheresis Autologous Primary central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
1066 Apheresis Allogeneic Myelodysplastic Syndrome/ Acute Myeloid Leukemia Hematology 2025 Standard Therapy Germany 62
1067 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 42
1068 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 55
1069 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 72
1070 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 58
1071 Apheresis Autologous Central nervous system lymphoma Hematology 2025 Standard Therapy Germany 65
1072 Apheresis Autologous Follicular lymphoma Hematology 2025 Standard Therapy Germany 67
1073 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1074 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 60
1075 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 64
1076 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 63
1077 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 67
1078 Apheresis Autologous Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 60
1079 Apheresis Autologous Hodgkin lymphoma rezidiv Hematology 2025 Standard Therapy Germany 65
1080 Apheresis Autologous Non-Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 64
1081 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 67
1082 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1083 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1084 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1085 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 66
1086 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
1087 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 60
1088 Apheresis Allogeneic Fanconi's Anemia Hematology 2025 Standard Therapy Ukraine 6
1089 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 69
1090 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Lithuania 54
1091 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Macedonia 56
1092 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy CROATIA 64
1093 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 75
1094 Apheresis Allogeneic T-cell Lymphoma Hematology 2025 Standard Therapy NETHERLANDS 65
1095 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
1096 Apheresis Allogeneic Myeloid Sarcoma Hematology 2025 Standard Therapy Brazil 48
1097 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 17
1098 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy United Kingdom 13
1099 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 69
1100 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 13
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?